When is someone who's not on Prozac and looking through rose-colored glasses going to revise the one year target estimate to something more realistic? This dog has shed 20% this month alone! One would have thought the slightly better than expected quarterly results would have kicked the price over $3 per share. In case you haven't already guessed, frustration with this stock has started to take hold.